XGEN:XETRA:XETRA-Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C USD Acc (EUR)

ETF | Others |

Last Closing

USD 28.63

Change

-1.16 (-3.88)%

Market Cap

N/A

Volume

2.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-02 )

ETFs Containing XGEN:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.67% 66% D+ 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.67% 65% D 64% D
Trailing 12 Months  
Capital Gain 3.90% 31% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.90% 30% F 36% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.59% 22% F 24% F
Dividend Return -1.59% 21% F 22% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 3.62% 91% A- 93% A
Risk Adjusted Return -43.92% 16% F 15% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.